Meghna Das Thakur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Meghna Das Thakur has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Akshata R. Udyavar
Affiliation Bioinformatics & Computational Biology, Genentech Inc., South San Francisco, California, United States of America
1 shared publicationAlexandre Vasiljevic
Team Fluid, INSERM U1028, CNRS UMR 5292, Lyon Neurosciences Recherche Center, Université Lyon 1, Lyon, France
1 shared publicationAmelia Au-Yeung
Affiliation Oncology Biomarker Development, Genentech Inc., South San Francisco, California, United States of America
1 shared publication- Anneleen Daemen
Department of Bioinformatics & Computational Biology, Genentech, Inc
1 shared publication - Aurelien Marabelle
University of Paris Saclay, Gustave Roussy Cancer Center, Villejuif, France
1 shared publication Carl J. Franz
Lake Tahoe Community College, South Lake Tahoe, CA, USA
1 shared publication
Latest Publications
- 31 May 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 170, 179-193
Immune contexture of paediatric cancers
- 31 May 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 170, 179-193
Immune contexture of paediatric cancers
- Open Access
- 31 December 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (12) , e0262198
Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B
Background: Colorectal cancer (CRC) is a leading cause of cancer-related deaths, with a 5% 5-year survival rate for metastatic disease, yet with limited therapeutic advancements due to insufficient understanding of and inability to accurately capture high-risk CRC patients who are most likely to recur. We aimed to improve high-risk classification by identifying biological pathways associated with outcome in adjuvant stage II/III CRC. Methods and findings: We included 1062 patients with stage III or high-risk stage II colon carcinoma from the prospective three-arm randomized phase 3 AVANT trial, and performed expression profiling to identify a prognostic signature. Data from validation cohort GSE39582, The Cancer Genome Atlas, and cell lines were used to further validate the prognostic biology. Our retrospective analysis of the adjuvant AVANT trial uncovered a prognostic signature capturing three biological functions—stromal, proliferative and immune—that outperformed the Consensus Molecular Subtypes (CMS) and recurrence prediction signatures like Oncotype Dx in an independent cohort. Importantly, within the immune component, high granzyme B (GZMB) expression had a significant prognostic impact while other individual T-effector genes were less or not prognostic. In addition, we found GZMB to be endogenously expressed in CMS2 tumor cells and to be prognostic in a T cell independent fashion. A limitation of our study is that these results, although robust and derived from a large dataset, still need to be clinically validated in a prospective study. Conclusions: This work furthers our understanding of the underlying biology that propagates stage II/III CRC disease progression and provides scientific rationale for future high-risk stratification and targeted treatment evaluation in biomarker defined subpopulations of resectable high-risk CRC. Our results also shed light on an alternative GZMB source with context-specific implications on the disease’s unique biology.
- 31 December 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (12) , e0262198
Open AccessTranscriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B
Background: Colorectal cancer (CRC) is a leading cause of cancer-related deaths, with a 5% 5-year survival rate for metastatic disease, yet with limited therapeutic advancements due to insufficient understanding of and inability to accurately capture high-risk CRC patients who are most likely to recur. We aimed to improve high-risk classification by identifying biological pathways associated with outcome in adjuvant stage II/III CRC. Methods and findings: We included 1062 patients with stage III or high-risk stage II colon carcinoma from the prospective three-arm randomized phase 3 AVANT trial, and performed expression profiling to identify a prognostic signature. Data from validation cohort GSE39582, The Cancer Genome Atlas, and cell lines were used to further validate the prognostic biology. Our retrospective analysis of the adjuvant AVANT trial uncovered a prognostic signature capturing three biological functions—stromal, proliferative and immune—that outperformed the Consensus Molecular Subtypes (CMS) and recurrence prediction signatures like Oncotype Dx in an independent cohort. Importantly, within the immune component, high granzyme B (GZMB) expression had a significant prognostic impact while other individual T-effector genes were less or not prognostic. In addition, we found GZMB to be endogenously expressed in CMS2 tumor cells and to be prognostic in a T cell independent fashion. A limitation of our study is that these results, although robust and derived from a large dataset, still need to be clinically validated in a prospective study. Conclusions: This work furthers our understanding of the underlying biology that propagates stage II/III CRC disease progression and provides scientific rationale for future high-risk stratification and targeted treatment evaluation in biomarker defined subpopulations of resectable high-risk CRC. Our results also shed light on an alternative GZMB source with context-specific implications on the disease’s unique biology.